To Ka Lun Aaron, Fok Yuen Ying Yvonne, Chong Ka Chun Marc, Lee Yuen Chi Joanne, Yiu Ling Shan Sandy
Hong Kong Association of Homeopathy, Hong Kong.
The School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong.
Homeopathy. 2017 May;106(2):79-86. doi: 10.1016/j.homp.2017.02.002. Epub 2017 Mar 17.
Glycaemic goals are not achieved in most patients with type II diabetes mellitus (T2DM), especially in those with long disease duration and taking multiple oral antidiabetic drugs (OAD). We aimed to investigate the effectiveness of individualized homeopathic treatment in glycaemic control.
Retrospective cohort study.
At least 6 months of individualized homeopathic treatment at a private homeopathic centre in Hong Kong.
Twenty-seven adults aged 37-84 years were treated with individualized homeopathic remedies between 2012 and 2015. Published data on 40 T2DM patients under standard conventional treatment in Hong Kong were used as a control.
Change in fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) at 12-month or the last follow-up, whichever is earlier.
Compared with the conventional treatment only group, the homeopathy group had higher baseline FPG (p = 0.044), and more patients had a long (>20 years) duration of diabetes (p = 0.006), and a history of cardiac events (p = 0.022). The mean difference in FPG in the homeopathy group was significantly greater than in the control after 12 months: -2.24 mmol/L (95% confidence interval [CI]: -3.47 to -1.01) vs 0.16 mmol/L (95% CI: -1.72 to 2.04), p = 0.001. The mean difference in glycated haemoglobin (HbA1c) was also significantly greater, -1.11% (95% CI: -2.17 to -0.05) vs 0.08% (95% CI: -1.37 to 1.53), p = 0.046. Poorer baseline glycaemic control was associated with better outcome (r = -0.750, p < 0.001), but not the duration of diabetes (r = 0.058, p = 0.772). The improvement was robust to sensitivity analyses.
Individualized homeopathic treatment was associated with better glycaemic control compared with standard conventional treatment alone.
大多数2型糖尿病（T2DM）患者未实现血糖目标，尤其是病程长且服用多种口服降糖药（OAD）的患者。我们旨在研究个体化顺势疗法治疗在血糖控制方面的有效性。
回顾性队列研究。
香港一家私人顺势疗法中心至少6个月的个体化顺势疗法治疗。
2012年至2015年间，27名年龄在37 - 84岁的成年人接受了个体化顺势疗法治疗。香港40名接受标准常规治疗的T2DM患者的已发表数据用作对照。
12个月或最后一次随访（以较早者为准）时空腹血糖（FPG）和糖化血红蛋白（HbA1c）的变化。
与仅接受常规治疗的组相比，顺势疗法组的基线FPG更高（p = 0.044），更多患者患有糖尿病的病程长（>20年）（p = 0.006），且有心脏事件史（p = 0.022）。12个月后，顺势疗法组FPG的平均差异显著大于对照组：-2.24 mmol/L（95%置信区间[CI]：-3.47至-1.01）对比0.16 mmol/L（95% CI：-1.72至2.04），p = 0.001。糖化血红蛋白（HbA1c）的平均差异也显著更大，-1.11%（95% CI：-2.17至-0.05）对比0.08%（95% CI：-1.37至1.53），p = 0.046。较差的基线血糖控制与更好的结果相关（r = -0.750，p < 0.001），但与糖尿病病程无关（r = 0.058，p = 0.772）。该改善在敏感性分析中具有稳健性。
与单独的标准常规治疗相比，个体化顺势疗法治疗与更好的血糖控制相关。
